collection
MENU ▼
Read by QxMD icon Read
search

Hepatology

shared collection
169 papers 100 to 500 followers
https://www.readbyqxmd.com/read/30075230/modified-page-b-score-predicts-the-risk-of-hepatocellular-carcinoma-in-asians-with-chronic-hepatitis-b-on-antiviral-therapy
#1
Ji Hyun Kim, Young Don Kim, Minjong Lee, Baek Gyu Jun, Tae Suk Kim, Ki Tae Suk, Seong Hee Kang, Moon Young Kim, Gab Jin Cheon, Dong Joon Kim, Soon Koo Baik, Dae Hee Choi
BACKGROUND & AIMS: Recently, the PAGE-B score and Toronto HCC risk index (THRI) have been developed to predict the risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB). We aimed to validate PAGE-B scores and THRI in Asian patients with CHB and suggested modified PAGE-B scores to improve the predictive performance. METHODS: From 2007 to 2017, we examined 3,001 Asian patients with CHB receiving entecavir/tenofovir therapy...
August 1, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/30063482/additional-role-of-liver-stiffness-measurement-in-stratifying-residual-hepatocellular-carcinoma-risk-predicted-by-serum-biomarkers-in-chronic-hepatitis-b-patients-under-antiviral-therapy
#2
Byeong G Song, Dong H Sinn, Sangah Chi, Kyunga Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon S Choi, Joon H Lee, Kwang C Koh, Seung W Paik
BACKGROUND: The risk of hepatocellular carcinoma (HCC) remains among patients who are treated with antiviral therapy (AVT). The degree of liver fibrosis has been suggested as an important biomarker to stratify the risk of developing HCC. We tested whether liver stiffness (LS) measured using transient elastography is useful over two noninvasive serum biomarkers of fibrosis [the aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4)]. PATIENTS AND METHODS: A retrospective cohort of 1014 CHB patients who were under AVT with nucleos(t)ide analogs for at least a year was analyzed...
July 30, 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30075229/statins-old-drugs-as-new-therapy-for-liver-diseases
#3
REVIEW
Elisa Pose, Jonel Trebicka, Rajeshwar P Mookerjee, Paolo Angeli, Pere Ginès
In addition to lowering cholesterol levels, statins have pleiotropic effects, particularly anti-inflammatory, antiangiogenic, and antifibrotic, that may be beneficial in some chronic inflammatory conditions. Statins have only recently been investigated as a potential treatment option in chronic liver diseases because of concerns related to their safety in patients with impaired liver function. A number of experimental studies in animal models of liver diseases have shown that statins decrease hepatic inflammation, fibrogenesis and portal pressure...
August 1, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/30002466/current-management-of-hepatic-encephalopathy
#4
REVIEW
Chathur Acharya, Jasmohan S Bajaj
Hepatic encephalopathy is a state of brain dysfunction resulting from decompensation of cirrhosis. The mortality and morbidity associated with the overt form of hepatic encephalopathy are high, and even the covert form associates with poor outcomes and poor quality of life. We know that the dysfunction is not just an acute insult to the brain but rather results in long-standing cognitive issues that get worse with each episode of HE. Hence, there is an urgency to accurately diagnose these conditions, start appropriate therapy, and to maintain remission...
July 13, 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29973706/refractory-ascites-in-liver-cirrhosis
#5
REVIEW
Danielle Adebayo, Shuet Fong Neong, Florence Wong
Ascites, a common complication of liver cirrhosis, eventually becomes refractory to diuretic therapy and sodium restriction in ~10% of patients. Multiple pathogenetic factors are involved in the development of refractory ascites, which ultimately lead to renal hypoperfusion and avid sodium retention. Therefore, renal dysfunction commonly accompanies refractory ascites. Management includes continuation of sodium restriction, which needs frequent reviews for adherence; and regular large volume paracentesis of 5 L or more with albumin infusions to prevent the development of paracentesis-induced circulatory dysfunction...
July 5, 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29928161/the-role-of-proton-pump-inhibitors-in-the-management-of-upper-gastrointestinal-disorders
#6
Muhammad Ali Khan, Colin W Howden
Proton pump inhibitors (PPIs) have been in use since the early 1990s and play a crucial role in the management of a number of conditions affecting the upper gastrointestinal tract, including gastroesophageal reflux disease, Barrett esophagus, eosinophilic esophagitis, and dyspepsia. PPIs also play an important role in the treatment of Helicobacter pylori infection and in the prevention of upper gastrointestinal tract ulcers and bleeding among patients taking antiplatelet therapy and/or nonsteroidal anti-inflammatory drugs...
March 2018: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30039640/review-article-systemic-treatment-of-hepatocellular-carcinoma
#7
REVIEW
Matthias Pinter, Markus Peck-Radosavljevic
BACKGROUND: The approval of the tyrosine kinase inhibitor sorafenib in 2007 marked a milestone in the treatment of hepatocellular carcinoma, as sorafenib was the first systemic therapy to show a survival benefit in patients with advanced hepatocellular carcinoma. Since then many drugs failed in the first- and second-line setting and it took almost another decade until further tyrosine kinase inhibitors succeeded in phase III trials. AIM: To summarise the evolving field of systemic therapy of hepatocellular carcinoma...
September 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29877316/hepatitis-b-virus-infection
#8
REVIEW
Man-Fung Yuen, Ding-Shinn Chen, Geoffrey M Dusheiko, Harry L A Janssen, Daryl T Y Lau, Stephen A Locarnini, Marion G Peters, Ching-Lung Lai
Hepatitis B virus (HBV) is a hepatotropic virus that can establish a persistent and chronic infection in humans through immune anergy. Currently, 3.5% of the global population is chronically infected with HBV, although the incidence of HBV infections is decreasing owing to vaccination and, to a lesser extent, the use of antiviral therapy to reduce the viral load of chronically infected individuals. The course of chronic HBV infection typically comprises different clinical phases, each of which potentially lasts for decades...
June 7, 2018: Nature Reviews. Disease Primers
https://www.readbyqxmd.com/read/29802949/noninvasive-prediction-of-esophageal-varices-by-stiffness-and-platelet-in-nonalcoholic-fatty-liver-disease-cirrhosis
#9
Salvatore Petta, Giada Sebastiani, Elisabetta Bugianesi, Mauro Viganò, Vincent Wai-Sun Wong, Annalisa Berzigotti, Anna Ludovica Fracanzani, Quentin M Anstee, Fabio Marra, Marco Barbara, Vincenza Calvaruso, Calogero Cammà, Vito Di Marco, Antonio Craxì, Victor de Ledinghen
BACKGROUND/AIM: Baveno VI and expanded Baveno VI criteria can avoid the need for esophagogastroduodenoscopy(EGD) to screen for varices needing treatment(VNT) in a substantial proportion of compensated patients with viral and/or alcoholic cirrhosis. This multicenter, cross-sectional study aims to validate these criteria in patients with compensated cirrhosis due to nonalcoholic fatty liver disease(NAFLD), accounting for possible differences in liver stiffness measurement(LSM) values between M and XL probes...
May 23, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29891100/treatment-of-chronic-hepatitis-c
#10
Xavier Forns, Christoph Sarrazin
No abstract text is available yet for this article.
August 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29756596/hepatic-encephalopathy-classification-and-treatment
#11
Jasmohan S Bajaj
No abstract text is available yet for this article.
April 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29628280/easl-clinical-practice-guidelines-management-of-alcohol-related-liver-disease
#12
(no author information available yet)
No abstract text is available yet for this article.
July 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29677098/update-treatment-for-hbv-infection-and-persistent-risk-for-hepatocellular-carcinoma-prospect-for-an-hbv-cure
#13
REVIEW
Joseph Yoo, Hie-Won Hann, Robert Coben, Mitchell Conn, Anthony J DiMarino
Since the discovery of the hepatitis B virus (HBV) by Blumberg et al. in 1965, its genome, sequence, epidemiology, and hepatocarcinogenesis have been elucidated. Globally, hepatitis B virus (HBV) is still responsible for the majority of hepatocellular carcinoma (HCC). HCC is the sixth-most common cancer in the world and the second-most common cancer death. The ultimate goal of treating HBV infection is the prevention of HCC. Fortunately, anti-HBV treatment with nucleos(t)ide analogues (NAs), which began with lamivudine in 1998, has resulted in remarkable improvements in the survival of patients with chronic hepatitis B and a reduced incidence of HCC...
April 20, 2018: Diseases (Basel)
https://www.readbyqxmd.com/read/29659382/tenofovir-versus-entecavir-for-the-treatment-of-acute-on-chronic-liver-failure-due-to-reactivation-of-chronic-hepatitis-b-with-genotypes-b-and-c
#14
Yue-Meng Wan, Yu-Hua Li, Zhi-Yuan Xu, Hua-Mei Wu, Ying Xu, Xi-Nan Wu, Jin-Hui Yang
BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) can be triggered by reactivation of chronic hepatitis B (CHB). Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are now the most potent antiviral agents for CHB. This study aimed to compare the short-term safety and efficacy of TDF with ETV in the treatment of ACLF due to reactivation of CHB [hepatitis B virus (HBV)-ACLF]. PATIENTS AND METHODS: In total, 67 consecutive patients with HBV-ACLF were divided into TDF group (n=32) receiving daily TDF (300 mg/d) and ETV group (n=35) receiving daily ETV (0...
April 13, 2018: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/29713021/risk-of-cardiomyopathy-and-cardiac-arrhythmias-in-patients-with-nonalcoholic-fatty-liver-disease
#15
REVIEW
Quentin M Anstee, Alessandro Mantovani, Herbert Tilg, Giovanni Targher
Nonalcoholic fatty liver disease (NAFLD) is a common, progressive liver disease that affects up to one-quarter of the adult population worldwide. The clinical and economic burden of NAFLD is mainly due to liver-related morbidity and mortality (nonalcoholic steatohepatitis, cirrhosis or hepatocellular carcinoma) and an increased risk of developing fatal and nonfatal cardiovascular disease, chronic kidney disease and certain types of extrahepatic cancers (for example, colorectal cancer and breast cancer). Additionally, there is now accumulating evidence that NAFLD adversely affects not only the coronary arteries (promoting accelerated coronary atherosclerosis) but also all other anatomical structures of the heart, conferring an increased risk of cardiomyopathy (mainly left ventricular diastolic dysfunction and hypertrophy, leading to the development of congestive heart failure), cardiac valvular calcification (mainly aortic-valve sclerosis), cardiac arrhythmias (mainly atrial fibrillation) and some cardiac conduction defects...
July 2018: Nature Reviews. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29628281/easl-clinical-practice-guidelines-management-of-hepatocellular-carcinoma
#16
(no author information available yet)
No abstract text is available yet for this article.
July 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29653741/easl-clinical-practice-guidelines-for-the-management-of-patients-with-decompensated-cirrhosis
#17
(no author information available yet)
No abstract text is available yet for this article.
August 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29715359/chronic-hepatitis-b-infection-a-review
#18
REVIEW
Lydia S Y Tang, Emily Covert, Eleanor Wilson, Shyam Kottilil
Importance: More than 240 million individuals worldwide are infected with chronic hepatitis B virus (HBV). Among individuals with chronic HBV infection who are untreated, 15% to 40% progress to cirrhosis, which may lead to liver failure and liver cancer. Observations: Pegylated interferon and nucleos(t)ide analogues (lamivudine, adefovir, entecavir, tenofovir disoproxil, and tenofovir alafenamide) suppress HBV DNA replication and improve liver inflammation and fibrosis...
May 1, 2018: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29517711/incidence-and-risk-factors-of-intrauterine-transmission-among-pregnant-women-with-chronic-hepatitis-b-virus-infection
#19
Songxu Peng, Zhihua Wan, Tingting Liu, Huiping Zhu, Yukai Du
GOALS: To identify the potential risk factors of hepatitis B virus (HBV) intrauterine transmission and predict the incidence of HBV intrauterine transmission among hepatitis B surface antigen-positive pregnant women with diverse viral load. BACKGROUND: The intrauterine transmission of HBV significantly contributes to the persistence of a high number of patients infected with HBV. However, its risk factors remain unclear. MATERIALS AND METHODS: A prospective study was performed on hepatitis B surface antigen-positive pregnant women who delivered from June 2012 to December 2016 at Wuhan Medical Care Center for Women and Children, Wuhan, China...
March 6, 2018: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/29551708/development-of-a-scoring-system-to-predict-hepatocellular-carcinoma-in-asians-on-antivirals-for-chronic-hepatitis-b
#20
Yao-Chun Hsu, Terry Cheuk-Fung Yip, Hsiu J Ho, Vincent Wai-Sun Wong, Yen-Tsung Huang, Hashem B El-Serag, Teng-Yu Lee, Ming-Shiang Wu, Jaw-Town Lin, Grace Lai-Hung Wong, Chun-Ying Wu
BACKGROUND & AIMS: The risk of hepatocellular carcinoma (HCC) during antiviral therapy in patients with chronic hepatitis B (CHB) is inadequately predicted by the scores built from untreated patients. We aimed at developing and validating a risk score to predict HCC in patients with CHB on entecavir or tenofovir treatment. METHODS: This study analysed population-wide data from the healthcare databases in Taiwan and Hong Kong to identify patients with CHB continuously receiving entecavir or tenofovir...
August 2018: Journal of Hepatology
label_collection
label_collection
4742
1
2
2018-04-11 01:47:59
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"